 |
|
|
| |
A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
M.H. van der Ree 1, J.M.L. de Vree 2, F. Stelma 1, S.B. Willemse 1, M. van der Valk 1, S. Rietdijk 1,3, R. Molenkamp 4, J. Schinkel 4, S. Hadi 5, M. Harbers 5, A. van Vliet 5, J. Udo de Haes 5, P. Grint 6, S. Neben 6, N. Gibson 6 and H.W. Reesink 1
1.Dep. of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
2.Dep. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands
3.Dep. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
4.Dep. of Medical Microbiology, Clinical Virology Laboratory, Academic Medical Center, Amsterdam, The Netherlands
5.PRA Healthsciences, Zuidlaren, The Netherlands
6.Regulus Therapeutics, San Diego, CA, USA
|
| |
|
|
|
|
|
